Abstract:Objective: To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. Method: We used the data acquired in the European First-Episode Schizophrenia Trial, an open, randomized trial (conducted in 14 countries) comparing 5 antipsychotic drugs in 498 patients aged 18-40 years with first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. DSM-IV diagnostic criteria were used. Patients were assessed between December 23, 2002 and January 14, 2006. Most subjects joined the study as inpatients and then continued with follow-ups in outpatient clinic visits. The Positive and Negative Syndrome Scale (PANSS) was administered at baseline and at 1, 3, 6, 9, and 12 months after randomization. We analyzed the scores on the PANSS hostility item in a subset of 302 patients showing at least minimal hostility (a score > 1) at baseline. We hypothesized (1) that the treatments would differ in their efficacy for hostility and (2) that olanzapine would be superior to haloperidol. Our primary statistical analysis tested the null hypothesis of no difference among the treatment groups in change in hostility over time. Secondary analysis addressed the question of whether the effects on hostility found in the primary analysis were specific to this item. All our analyses were post hoc. Results: The primary analysis of hostility indicated an effect of differences between treatments (F-4,F-889 = 4.02, P = .0031). Post hoc treatment-group contrasts for hostility change showed that, at months 1 and 3, olanzapine was significantly superior (P < .05) to haloperidol, quetiapine, and amisulpride in reducing hostility. Secondary analyses demonstrated that these results were at least partly specific to hostility. Conclusions: Both hypotheses were supported. Olanzapine appears to be a superior treatment for hostility in early phases of therapy for first-episode schizophrenia, schizoaffective disorder, and schizophreniform disorder. This efficacy advantage of olanzapine must be weighed against its adverse metabolic effects and propensity to cause weight gain. Trial Registration: ISRCTN Register Identifier: ISRCTN68736636 J Clin Psychiatry 2011;72(7):955-961 (C) Copyright 2011 Physicians Postgraduate Press, Inc.

Insight and Hostility As Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial

Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies

Predictors of Discontinuation of Antipsychotic Medication and Subsequent Outcomes in the European First Episode Schizophrenia Trial (EUFEST).

Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies

Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.

Unmet Needs in Patients with First-Episode Schizophrenia: a Longitudinal Perspective

The European First Episode Schizophrenia Trial (EUFEST): Rationale and Design of the Trial

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Differential Effects of Antipsychotic Drugs on Insight in First Episode Schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST)

Drug Attitude As Predictor for Effectiveness in First-Episode Schizophrenia: Results of an Open Randomized Trial (EUFEST).

Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).

Treatment of depression in first episode of schizophrenia: results from EUFEST.

Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders

Predictors of clinical insight in first-episode psychosis: Different patterns in men and women

Persistent Negative Symptoms in First Episode Patients with Schizophrenia: Results from the European First Episode Schizophrenia Trial

Do Antipsychotics Affect Insight in Psychosis Differentially? Data from the EUFEST Trial.

Clinical, psychological and brain imaging investigation of first episode psychosis patients treated at Semmelweis University, Department of Psychiatry and Psychotherapy, Budapest, Hungary

Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention

Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study

Stratification and prediction of remission in first-episode psychosis patients OPTIMISE